Literature DB >> 8913326

Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER).

T Kanda1, M Kurokawa, S Tamura, J Nakamura, A Ishii, Y Kuwana, T Serikawa, J Yamada, K Ishihara, M Sasa.   

Abstract

The spontaneously epileptic rat (SER), a double mutant, manifests both tonic and absence-like seizures. The effect of topiramate, a novel antiepileptic drug, on the extracellular levels of excitatory amino acids (EAA) in the hippocampus of SER was investigated using in vivo microdialysis. The basal levels of glutamate and aspartate in dialysates of hippocampus in SER were 2- to 3-fold higher than those in normal Wistar rats. Both the dose-response relationship and the time course of the suppression of tonic seizures by topiramate were similar to the attenuation of glutamate level in SER. Topiramate (40 mg/kg i.p.) significantly (P < 0.05) reduced both glutamate and aspartate levels in SER while showing no effect on normal Wistar rats. These findings suggest that topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of SER. This effect may, at least in part, be related to the anticonvulsant activity of topiramate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8913326     DOI: 10.1016/0024-3205(96)00492-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  15 in total

1.  Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study.

Authors:  P F Behrens; H Langemann; R Strohschein; J Draeger; J Hennig
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

Review 2.  Organotypic Spinal Cord Culture: a Proper Platform for the Functional Screening.

Authors:  Sareh Pandamooz; Mohammad Nabiuni; Jaleel Miyan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

3.  Topiramate raises anterior cingulate cortex glutamine levels in healthy men; a 4.0 T magnetic resonance spectroscopy study.

Authors:  Constance M Moore; Megan Wardrop; Blaise deB Frederick; Perry F Renshaw
Journal:  Psychopharmacology (Berl)       Date:  2006-08-31       Impact factor: 4.530

4.  Effect of ceftriaxone and topiramate treatments on naltrexone-precipitated morphine withdrawal and glutamate receptor desensitization in the rat locus coeruleus.

Authors:  María Carmen Medrano; Aitziber Mendiguren; Joseba Pineda
Journal:  Psychopharmacology (Berl)       Date:  2015-03-20       Impact factor: 4.530

Review 5.  Glutamatergic Mechanisms Associated with Seizures and Epilepsy.

Authors:  Melissa Barker-Haliski; H Steve White
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-22       Impact factor: 6.915

6.  Topiramate-antagonism of L-glutamate-induced paroxysms in planarians.

Authors:  Robert B Raffa; Kristin E Finno; Christopher S Tallarida; Scott M Rawls
Journal:  Eur J Pharmacol       Date:  2010-09-19       Impact factor: 4.432

7.  Antiischemic effects of topiramate in a transient global forebrain ischemia model: a neurochemical, histological, and behavioral evaluation.

Authors:  S H Khan; Sandra Lea Wright; Ali Banigesh; Hiro Miyashita; Kathryn Todd; Susan Jean Hemmings; Tom Wishart; Ashfaq Shuaib
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

8.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

Review 9.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 10.  Topiramate for neuropathic pain and fibromyalgia in adults.

Authors:  Philip J Wiffen; Sheena Derry; Michael P T Lunn; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2013-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.